NGM Biopharmaceuticals ngmbio.com


Public lists: Pharma Startups (4732)

NGM Biopharmaceuticals is a drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases. The Company is focused on discovering the next generation of therapeutics that will fundamentally change the treatment paradigm for the growing population of diabetes and obesity patients worldwide. NGM has established collaborations with Daiichi Sankyo in the area of beta cell regeneration, and with JDRF to di...Show all

NGM Biopharmaceuticals is a drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases. The Company is focused on discovering the next generation of t...Show all

Company (Alive / Active)

Phone: 650-243-5575

Fax:

630 Gateway Boulevard

South San Francisco, 94080
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
NGM Biopharmaceuticals $290.8M Mar 23, 2015
See all 78 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related NGM Biopharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Competitors

Company Status Description Investors

Innoviva

Brisbane, California, United States
IPO / Went publicInnoviva, formerly known as Theravance, is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible...Show allLogin to see details

Trevena

King Of Prussia, Pennsylvania, United States
IPO / Went publicTrevena is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G protein coupled receptor (GPCR) targeted medicines. Despite the past success of GPCR drugs, there is a significant opportunity to enhance their therapeutic properties by specifically activating or deactivating selected receptor-mediated signals. Trevena's expertise lies in understanding which signaling pathways downstream of a GPCR are associated with beneficial versus adverse biolog...Show allLogin to see details
See all 78 competitors